Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222.

Singh AK, Fan Y, Balut C, Alani S, Manelli AM, Swensen AM, Jia Y, Neelands TR, Vortherms TA, Liu B, Searle XB, Wang X, Gao W, Hwang TC, Ren HY, Cyr D, Kym PR, Conrath K, Tse C.

J Pharmacol Exp Ther. 2020 Jan;372(1):107-118. doi: 10.1124/jpet.119.261800. Epub 2019 Nov 15.

PMID:
31732698
2.

Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.

Kym PR, Wang X, Pizzonero M, Van der Plas SE.

Prog Med Chem. 2018;57(1):235-276. doi: 10.1016/bs.pmch.2018.01.001. Epub 2018 Feb 19. Review.

PMID:
29680149
3.

TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development.

Garami A, Pakai E, McDonald HA, Reilly RM, Gomtsyan A, Corrigan JJ, Pinter E, Zhu DXD, Lehto SG, Gavva NR, Kym PR, Romanovsky AA.

Acta Physiol (Oxf). 2018 Jul;223(3):e13038. doi: 10.1111/apha.13038. Epub 2018 Feb 16.

4.

TRPV3 modulates nociceptive signaling through peripheral and supraspinal sites in rats.

McGaraughty S, Chu KL, Xu J, Leys L, Radek RJ, Dart MJ, Gomtsyan A, Schmidt RG, Kym PR, Brederson JD.

J Neurophysiol. 2017 Aug 1;118(2):904-916. doi: 10.1152/jn.00104.2017. Epub 2017 May 3.

5.

Stereoselective Synthesis of a Dipyridyl Transient Receptor Potential Vanilloid-3 (TRPV3) Antagonist.

Voight EA, Daanen JF, Schmidt RG, Gomtsyan A, Dart MJ, Kym PR.

J Org Chem. 2016 Dec 2;81(23):12060-12064. Epub 2016 Nov 14.

PMID:
27934457
6.

TRPV1 ligands with hyperthermic, hypothermic and no temperature effects in rats.

Gomtsyan A, McDonald HA, Schmidt RG, Daanen JF, Voight EA, Segreti JA, Puttfarcken PS, Reilly RM, Kort ME, Dart MJ, Kym PR.

Temperature (Austin). 2015 May 22;2(2):297-301. doi: 10.1080/23328940.2015.1046013. eCollection 2015 Apr-Jun.

7.

Feeling hot, feeling cold: TRP channels-a great story unfolds.

Vetter I, Kym PR, Szallasi A.

Temperature (Austin). 2015 May 26;2(2):150-1. doi: 10.1080/23328940.2015.1047721. eCollection 2015 Apr-Jun.

8.

Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.

Gomtsyan A, Schmidt RG, Bayburt EK, Gfesser GA, Voight EA, Daanen JF, Schmidt DL, Cowart MD, Liu H, Altenbach RJ, Kort ME, Clapham B, Cox PB, Shrestha A, Henry R, Whittern DN, Reilly RM, Puttfarcken PS, Brederson JD, Song P, Li B, Huang SM, McDonald HA, Neelands TR, McGaraughty SP, Gauvin DM, Joshi SK, Banfor PN, Segreti JA, Shebley M, Faltynek CR, Dart MJ, Kym PR.

J Med Chem. 2016 May 26;59(10):4926-47. doi: 10.1021/acs.jmedchem.6b00287. Epub 2016 May 2.

PMID:
27077528
9.

Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.

Voight EA, Gomtsyan AR, Daanen JF, Perner RJ, Schmidt RG, Bayburt EK, DiDomenico S, McDonald HA, Puttfarcken PS, Chen J, Neelands TR, Bianchi BR, Han P, Reilly RM, Franklin PH, Segreti JA, Nelson RA, Su Z, King AJ, Polakowski JS, Baker SJ, Gauvin DM, Lewis LR, Mikusa JP, Joshi SK, Faltynek CR, Kym PR, Kort ME.

J Med Chem. 2014 Sep 11;57(17):7412-24. doi: 10.1021/jm500916t. Epub 2014 Aug 21.

PMID:
25100568
10.

Transient receptor potential channel ankyrin-1 is not a cold sensor for autonomic thermoregulation in rodents.

de Oliveira C, Garami A, Lehto SG, Pakai E, Tekus V, Pohoczky K, Youngblood BD, Wang W, Kort ME, Kym PR, Pinter E, Gavva NR, Romanovsky AA.

J Neurosci. 2014 Mar 26;34(13):4445-52. doi: 10.1523/JNEUROSCI.5387-13.2014.

11.

Targeting TRP channels for pain relief.

Brederson JD, Kym PR, Szallasi A.

Eur J Pharmacol. 2013 Sep 15;716(1-3):61-76. doi: 10.1016/j.ejphar.2013.03.003. Epub 2013 Mar 14. Review.

PMID:
23500195
12.

In Vitro and in Vivo Assays for the Discovery of Analgesic Drugs Targeting TRP Channels.

Chen J, Reilly RM, Kym PR, Joshi S.

In: Zhu MX, editor. TRP Channels. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 18.

13.

Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.

Reilly RM, McDonald HA, Puttfarcken PS, Joshi SK, Lewis L, Pai M, Franklin PH, Segreti JA, Neelands TR, Han P, Chen J, Mantyh PW, Ghilardi JR, Turner TM, Voight EA, Daanen JF, Schmidt RG, Gomtsyan A, Kort ME, Faltynek CR, Kym PR.

J Pharmacol Exp Ther. 2012 Aug;342(2):416-28. doi: 10.1124/jpet.111.190314. Epub 2012 May 8.

PMID:
22570364
14.

TRPV1 antagonists: clinical setbacks and prospects for future development.

Kort ME, Kym PR.

Prog Med Chem. 2012;51:57-70. doi: 10.1016/B978-0-12-396493-9.00002-9. Review. No abstract available.

PMID:
22520471
15.

Species comparison and pharmacological characterization of human, monkey, rat, and mouse TRPA1 channels.

Bianchi BR, Zhang XF, Reilly RM, Kym PR, Yao BB, Chen J.

J Pharmacol Exp Ther. 2012 May;341(2):360-8. doi: 10.1124/jpet.111.189902. Epub 2012 Feb 7.

PMID:
22319196
16.

Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.

Yeh VS, Beno DW, Brodjian S, Brune ME, Cullen SC, Dayton BD, Dhaon MK, Falls HD, Gao J, Grihalde N, Hajduk P, Hansen TM, Judd AS, King AJ, Klix RC, Larson KJ, Lau YY, Marsh KC, Mittelstadt SW, Plata D, Rozema MJ, Segreti JA, Stoner EJ, Voorbach MJ, Wang X, Xin X, Zhao G, Collins CA, Cox BF, Reilly RM, Kym PR, Souers AJ.

J Med Chem. 2012 Feb 23;55(4):1751-7. doi: 10.1021/jm201524g. Epub 2012 Feb 10.

PMID:
22263872
17.

Capsaicin-induced inhibition of platelet aggregation is not mediated by transient receptor potential vanilloid type 1.

Mittelstadt SW, Nelson RA, Daanen JF, King AJ, Kort ME, Kym PR, Lubbers NL, Cox BF, Lynch JJ 3rd.

Blood Coagul Fibrinolysis. 2012 Jan;23(1):94-7. doi: 10.1097/MBC.0b013e32834ddf18.

PMID:
22089942
18.

TRPV1 antagonist, A-889425, inhibits mechanotransmission in a subclass of rat primary afferent neurons following peripheral inflammation.

Brederson JD, Chu KL, Reilly RM, Brown BS, Kym PR, Jarvis MF, McGaraughty S.

Synapse. 2012 Mar;66(3):187-95. doi: 10.1002/syn.20992. Epub 2011 Dec 13.

PMID:
21953601
19.

Analgesic potential of TRPV3 antagonists.

Reilly RM, Kym PR.

Curr Top Med Chem. 2011;11(17):2210-5. Review.

PMID:
21671874
20.

Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation.

Chen J, Joshi SK, DiDomenico S, Perner RJ, Mikusa JP, Gauvin DM, Segreti JA, Han P, Zhang XF, Niforatos W, Bianchi BR, Baker SJ, Zhong C, Simler GH, McDonald HA, Schmidt RG, McGaraughty SP, Chu KL, Faltynek CR, Kort ME, Reilly RM, Kym PR.

Pain. 2011 May;152(5):1165-72. doi: 10.1016/j.pain.2011.01.049. Epub 2011 Mar 12.

PMID:
21402443
21.

TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic pain.

Chu KL, Chandran P, Joshi SK, Jarvis MF, Kym PR, McGaraughty S.

Brain Res. 2011 Jan 19;1369:158-66. doi: 10.1016/j.brainres.2010.10.101. Epub 2010 Nov 1.

PMID:
21047496
22.

A-995662 [(R)-8-(4-methyl-5-(4-(trifluoromethyl)phenyl)oxazol-2-ylamino)-1,2,3,4-tetrahydronaphthalen-2-ol], a novel, selective TRPV1 receptor antagonist, reduces spinal release of glutamate and CGRP in a rat knee joint pain model.

Puttfarcken PS, Han P, Joshi SK, Neelands TR, Gauvin DM, Baker SJ, Lewis LG, Bianchi BR, Mikusa JP, Koenig JR, Perner RJ, Kort ME, Honore P, Faltynek CR, Kym PR, Reilly RM.

Pain. 2010 Aug;150(2):319-26. doi: 10.1016/j.pain.2010.05.015. Epub 2010 Jun 19.

PMID:
20621685
23.

Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists.

Perner RJ, Koenig JR, Didomenico S, Gomtsyan A, Schmidt RG, Lee CH, Hsu MC, McDonald HA, Gauvin DM, Joshi S, Turner TM, Reilly RM, Kym PR, Kort ME.

Bioorg Med Chem. 2010 Jul 1;18(13):4821-9. doi: 10.1016/j.bmc.2010.04.099. Epub 2010 May 10.

PMID:
20570528
24.

In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.

King AJ, Segreti JA, Larson KJ, Souers AJ, Kym PR, Reilly RM, Collins CA, Voorbach MJ, Zhao G, Mittelstadt SW, Cox BF.

Eur J Pharmacol. 2010 Jul 10;637(1-3):155-61. doi: 10.1016/j.ejphar.2010.03.056. Epub 2010 Apr 10.

PMID:
20385122
25.

TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats.

McGaraughty S, Chu KL, Perner RJ, Didomenico S, Kort ME, Kym PR.

Mol Pain. 2010 Mar 5;6:14. doi: 10.1186/1744-8069-6-14.

26.

Analgesic potential of TRPV1 antagonists.

Kym PR, Kort ME, Hutchins CW.

Biochem Pharmacol. 2009 Aug 1;78(3):211-6. doi: 10.1016/j.bcp.2009.02.014. Epub 2009 Mar 5.

PMID:
19481638
27.

Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.

King AJ, Segreti JA, Larson KJ, Souers AJ, Kym PR, Reilly RM, Zhao G, Mittelstadt SW, Cox BF.

J Pharmacol Exp Ther. 2009 Aug;330(2):526-31. doi: 10.1124/jpet.109.154047. Epub 2009 May 28.

PMID:
19478132
28.

TRPA1: the species difference.

Chen J, Kym PR.

J Gen Physiol. 2009 Jun;133(6):623-5. doi: 10.1085/jgp.200910246. No abstract available.

29.

Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats.

McGaraughty S, Segreti JA, Fryer RM, Brown BS, Faltynek CR, Kym PR.

Brain Res. 2009 May 1;1268:58-67. doi: 10.1016/j.brainres.2009.02.018. Epub 2009 Feb 21.

PMID:
19236852
30.

Pore dilation occurs in TRPA1 but not in TRPM8 channels.

Chen J, Kim D, Bianchi BR, Cavanaugh EJ, Faltynek CR, Kym PR, Reilly RM.

Mol Pain. 2009 Jan 21;5:3. doi: 10.1186/1744-8069-5-3.

31.

Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.

Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR.

Pain. 2009 Mar;142(1-2):27-35. doi: 10.1016/j.pain.2008.11.004. Epub 2009 Jan 9.

PMID:
19135797
32.

Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.

Judd AS, Souers AJ, Kym PR.

Curr Top Med Chem. 2008;8(13):1152-7. Review.

PMID:
18782010
33.

Molecular determinants of species-specific activation or blockade of TRPA1 channels.

Chen J, Zhang XF, Kort ME, Huth JR, Sun C, Miesbauer LJ, Cassar SC, Neelands T, Scott VE, Moreland RB, Reilly RM, Hajduk PJ, Kym PR, Hutchins CW, Faltynek CR.

J Neurosci. 2008 May 7;28(19):5063-71. doi: 10.1523/JNEUROSCI.0047-08.2008.

34.

Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.

Zhao G, Souers AJ, Voorbach M, Falls HD, Droz B, Brodjian S, Lau YY, Iyengar RR, Gao J, Judd AS, Wagaw SH, Ravn MM, Engstrom KM, Lynch JK, Mulhern MM, Freeman J, Dayton BD, Wang X, Grihalde N, Fry D, Beno DW, Marsh KC, Su Z, Diaz GJ, Collins CA, Sham H, Reilly RM, Brune ME, Kym PR.

J Med Chem. 2008 Feb 14;51(3):380-3. doi: 10.1021/jm7013887. Epub 2008 Jan 10.

PMID:
18183944
35.

Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists.

Kym PR, Judd AS, Lynch JK, Iyengar R, Vasudevan A, Souers AJ.

Curr Top Med Chem. 2007;7(15):1471-88. Review.

PMID:
17897033
36.

Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.

Liu G, Lynch JK, Freeman J, Liu B, Xin Z, Zhao H, Serby MD, Kym PR, Suhar TS, Smith HT, Cao N, Yang R, Janis RS, Krauser JA, Cepa SP, Beno DW, Sham HL, Collins CA, Surowy TK, Camp HS.

J Med Chem. 2007 Jun 28;50(13):3086-100. Epub 2007 May 27.

PMID:
17530838
37.

Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators.

Zhao G, Iyengar RR, Judd AS, Cool B, Chiou W, Kifle L, Frevert E, Sham H, Kym PR.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3254-7. Epub 2007 Apr 10.

PMID:
17451949
38.

Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.

Judd AS, Souers AJ, Wodka D, Zhao G, Mulhern MM, Iyengar RR, Gao J, Lynch JK, Freeman JC, Falls HD, Brodjian S, Dayton BD, Reilly RM, Gintant G, Limberis JT, Mikhail A, Leitza ST, Houseman KA, Diaz G, Bush EN, Shapiro R, Knourek-Segel V, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2365-71. Epub 2006 Dec 1.

PMID:
17350253
39.

An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.

Iyengar RR, Lynch JK, Mulhern MM, Judd AS, Freeman JC, Gao J, Souers AJ, Zhao G, Wodka D, Doug Falls H, Brodjian S, Dayton BD, Reilly RM, Swanson S, Su Z, Martin RL, Leitza ST, Houseman KA, Diaz G, Collins CA, Sham HL, Kym PR.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):874-8. Epub 2006 Dec 1.

PMID:
17234405
40.

Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.

Souers AJ, Iyengar RR, Judd AS, Beno DW, Gao J, Zhao G, Brune ME, Napier JJ, Mulhern MM, Lynch JK, Freeman JC, Wodka D, Chen CJ, Falls HD, Brodjian S, Dayton BD, Diaz GJ, Bush EN, Shapiro R, Droz BA, Knourek-Segel V, Hernandez LE, Marsh KC, Reilly RM, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):884-9. Epub 2006 Dec 1.

PMID:
17188866
41.

Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.

Lynch JK, Freeman JC, Judd AS, Iyengar R, Mulhern M, Zhao G, Napier JJ, Wodka D, Brodjian S, Dayton BD, Falls D, Ogiela C, Reilly RM, Campbell TJ, Polakowski JS, Hernandez L, Marsh KC, Shapiro R, Knourek-Segel V, Droz B, Bush E, Brune M, Preusser LC, Fryer RM, Reinhart GA, Houseman K, Diaz G, Mikhail A, Limberis JT, Sham HL, Collins CA, Kym PR.

J Med Chem. 2006 Nov 2;49(22):6569-84.

PMID:
17064075
42.

Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety.

Basso AM, Bratcher NA, Gallagher KB, Cowart MD, Zhao C, Sun M, Esbenshade TA, Brune ME, Fox GB, Schmidt M, Collins CA, Souers AJ, Iyengar R, Vasudevan A, Kym PR, Hancock AA, Rueter LE.

Eur J Pharmacol. 2006 Jul 1;540(1-3):115-20. Epub 2006 May 6.

PMID:
16765941
43.

Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.

Kym PR, Souers AJ, Campbell TJ, Lynch JK, Judd AS, Iyengar R, Vasudevan A, Gao J, Freeman JC, Wodka D, Mulhern M, Zhao G, Wagaw SH, Napier JJ, Brodjian S, Dayton BD, Reilly RM, Segreti JA, Fryer RM, Preusser LC, Reinhart GA, Hernandez L, Marsh KC, Sham HL, Collins CA, Polakowski JS.

J Med Chem. 2006 Apr 6;49(7):2339-52.

PMID:
16570930
44.

Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists.

Blackburn C, LaMarche MJ, Brown J, Che JL, Cullis CA, Lai S, Maguire M, Marsilje T, Geddes B, Govek E, Kadambi V, Doherty C, Dayton B, Brodjian S, Marsh KC, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2006 May 15;16(10):2621-7. Epub 2006 Mar 9.

PMID:
16524729
45.

Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.

Vasudevan A, Souers AJ, Freeman JC, Verzal MK, Gao J, Mulhern MM, Wodka D, Lynch JK, Engstrom KM, Wagaw SH, Brodjian S, Dayton B, Falls DH, Bush E, Brune M, Shapiro RD, Marsh KC, Hernandez LE, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5293-7. Epub 2005 Oct 3.

PMID:
16203136
46.

Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.

Kym PR, Iyengar R, Souers AJ, Lynch JK, Judd AS, Gao J, Freeman J, Mulhern M, Zhao G, Vasudevan A, Wodka D, Blackburn C, Brown J, Che JL, Cullis C, Lai SJ, LaMarche MJ, Marsilje T, Roses J, Sells T, Geddes B, Govek E, Patane M, Fry D, Dayton BD, Brodjian S, Falls D, Brune M, Bush E, Shapiro R, Knourek-Segel V, Fey T, McDowell C, Reinhart GA, Preusser LC, Marsh K, Hernandez L, Sham HL, Collins CA.

J Med Chem. 2005 Sep 22;48(19):5888-91.

PMID:
16161992
47.

Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists.

Vasudevan A, LaMarche MJ, Blackburn C, Che JL, Luchaco-Cullis CA, Lai S, Marsilje TH, Patane MA, Souers AJ, Wodka D, Geddes B, Chen S, Brodjian S, Falls DH, Dayton BD, Bush E, Brune M, Shapiro RD, Marsh KC, Hernandez LE, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4174-9.

PMID:
16085414
48.

Identification of aminopiperidine benzamides as MCHr1 antagonists.

Vasudevan A, Verzal MK, Wodka D, Souers AJ, Blackburn C, Che JL, Lai S, Brodjian S, Falls DH, Dayton BD, Govek E, Daniels T, Geddes B, Marsh KC, Hernandez LE, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3412-6.

PMID:
15950463
49.

Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.

Souers AJ, Gao J, Wodka D, Judd AS, Mulhern MM, Napier JJ, Brune ME, Bush EN, Brodjian SJ, Dayton BD, Shapiro R, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2752-7.

PMID:
15911251
50.

Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ.

J Pharmacol Exp Ther. 2005 Jul;314(1):191-200. Epub 2005 Mar 22.

PMID:
15784656

Supplemental Content

Support Center